In the present study, based on the group's previous research, we found that the molecular biological mechanism associated with ONSMP inhibition of myocardial fibrosis in heart failure using a network pharmacology approach may also involve baicalin, vitamin D, resveratrol, tanshinone IIA, emodin, 15,16-dihydrotanshinone-i, and other active ingredients acting on β1-AR, AC6, EPAC1, RAP1A, STAT3, and CCND1 to regulate the cAMP/Rap1 signaling pathway. The gene discussed is RAP1A; the disease is heart failure.